## HACKETTSTOWN REGIONAL MEDICAL CENTER CARDIO PULMONARY POLICY MANUAL BRONCHODILATOR ADMINISTRATION DURING PULMONARY FUNCTION TEST FOR PATIENTS 16 AND OLDER

\_\_\_\_\_\_

Effective Date: August 2009 Policy No: 4B.002

Cross Referenced: Origin: Cardio Pulmonary

Reviewed Date: 02/16 Authority: Cardio/Pulmonary Manager

Revised Date: 04/12 Page: 1 of 1

Purpose: To provide a protocol for Bronchodilator Administration during a PFT.

Procedure: The patient will receive a bronchodilator as part of a Pulmonary Function Test if the Forced Vital Capacity (FVC) maneuver falls below 80% as outlined.

Albuterol 2.5mg/3ml aerosol treatment to be given if the patient meets the following criteria:

- Patient is currently not receiving bronchodilator therapy, OR
- Patient is currently receiving Levalbuterol 1.25 mg/3ml aerosol treatment, OR
- Patient is currently receiving nebulized Albuterol 2.5mg therapy

Albuterol 1.25 mg/3ml aerosol treatment to be given if the patient meets the following criteria:

- Baseline HR > 110 bpm, OR
- Patient is currently receiving Levalbuterol 0.63 mg/3ml aerosol treatment, OR
- Patient is currently receiving beta-agonist Inhaler therapy, OR
- Patient is currently receiving nebulized Duoneb (ipratropium 0.5mg/albuterol 2.5mg).

If the patient is currently receiving nebulizer treatments and a dose is due, then the ordered dose will be given.

Prevention of therapeutic duplication or overdose:

Patients should start PFT at least 2 hours AFTER receipt of last inhaled/nebulized bronchodilator therapy – or hold scheduled dose until completion of PFT (or once FVC <80%).

Complete paperwork with patient identification label for bronchodilator administration, fax paperwork to pharmacy.

• This policy was approved by the Pharmacy & Therapeutics Committee, May 2010.